Skip to main content
. 2017 May 5;108(5):987–994. doi: 10.1111/cas.13221

Table 2.

Stratified PFS assessed by independent radiologist and investigator

Treatment Patients PFS, months Hazard ratio P‐value
Group n Median 90% CI HR 90% CI
Evaluated by independent radiologist
Prior taxane therapy No Nab‐paclitaxel 71 10.9 8.5, 12.5 1.05 0.72, 1.53 0.824
Docetaxel 71 9.9 7.8, 12.6
Yes Nab‐paclitaxel 27 8.4 6.9, 12.6 1.73 0.94, 3.17 0.133
Docetaxel 28 15.3 11.2, 18.1
Evaluated by investigator
Prior taxane therapy No Nab‐paclitaxel 71 11.3 9.4, 14.2 0.73 0.51, 1.06 0.166
Docetaxel 71 9.8 7.8, 11.1
Yes Nab‐paclitaxel 27 9.8 8.4, 16.5 0.99 0.56, 1.75 0.983
Docetaxel 28 12.5 9.3, 15.4

Analysis set: full analysis set. †Cox's proportional hazards model was used. CI, confidence interval; HR, hazard ratio; n, number of patients; PFS, progression‐free survival.